Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis

(MedPage Today) — SAN FRANCISCO — The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed.
The trial tested two doses of…